Executive search firm, Slone Partners, announces the placement of Roger Moody as Chief Financial Officer with Clinical Genomics. Moody is a reputable industry expert with a proven track record in leading finance and operations for rapidly growing companies.

Clinical Genomics is a leading provider of cancer testing solutions that develops innovative products to improve early detection of colorectal cancer in both the screening and cancer recurrence setting. Founded in 2006, the company now holds a broad intellectual property portfolio including more than 20 patents.

In his new role, Moody will direct all strategic and tactical financial operations. His extensive experience in managing rapid growth and delivering for investors will be instrumental in achieving Clinical Genomics’ expansion objectives.

“We are thrilled to welcome Roger to our leadership team. His well-rounded executive experience will be a tremendous asset to Clinical Genomics as we enter our most important growth phase to date. Slone Partners has been instrumental in securing Roger, and we are thankful to have been able to recruit someone of his caliber. We firmly believe that Roger will be key in executing on the mission and long term value we are building,” said Lawrence LaPointe, PhD, CEO of Clinical Genomics.

Prior to joining Clinical Genomics, Moody served as Chief Executive Officer and remains a Board Director of GlySure Limited, a leading UK-based company specializing in continuous glucose monitoring (CGM). Prior to GlySure, Moody held several leadership positions including the role of Chief Financial Officer at Nanosphere, Inc. He also served as Chief Financial Officer at Medsn, Inc. prior to becoming the Executive Vice President, Managing Director and then Chief Operating Officer following its sale to Indegene.

Moody earned a Bachelor of Science in Finance from Syracuse University and a Master of Business Administration with an emphasis in Finance from the Graduate School of Business at the University of Chicago.

About Slone Partners

Slone Partners delivers the leaders who build amazing organizations – People Are Our Science™. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, research, diagnostics, precision medicine and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, Los Angeles, San Diego, Dallas, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to exceptional clients. Our full suite of services includes identifying, negotiating with, onboarding, and relocating talent, in addition to post-placement mentoring, success monitoring, and culture fit services.

To learn more about Slone Partners value proposition and processes, visit https://www.slonepartners.com/.

About Clinical Genomics

Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, to COLVERA™, a proprietary blood test identifying circulating tumor DNA in patient’s post-treatment for early detection of recurrence and residual disease. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.

For more information, please visit http://www.clinicalgenomics.com and http://www.colveratest.com.